Moderna researchers at work in the company’s lab. The FDA’s reversal of its earlier refusal to review mRNA-1010, the seasonal flu vaccine being developed by Moderna accelerated a revival of its shares ...
WASHINGTON (AP) — The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after all, resolving a dispute that had blocked the company’s application for the first-of ...
WASHINGTON (AP) — The Food and Drug Administration will consider whether to approve Moderna's new flu vaccine after all, resolving a dispute that had blocked the company's application for the first-of ...
Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...
Moderna said the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing an earlier decision to refuse to accept the application. The FDA is slated to make a ...
A federal judge in Delaware has thrown out two key defenses Moderna (MRNA) had been claiming in its ongoing patent litigation with Arbutus Biopharma (ABUS) regarding its mRNA COVID-19 vaccine. Judge ...
The Food and Drug Administration has reversed its shocking refusal to consider Moderna’s mRNA flu vaccine for approval. The refusal was revealed last week in a sharply worded press release from ...
Matthew Herper covers medical innovation — both its promise and its perils. Well, that didn’t take long. It took all of one week to go from an announcement that the Food and Drug Administration was ...
The FDA will consider whether to approve Moderna's new flu vaccine after all, resolving a dispute that had blocked the company's application for the first-of-its-kind shot. Moderna announced the ...
The U.S. Food and Drug Administration will review a messenger RNA (mRNA) flu vaccine for approval, according to its maker, Moderna. The decision is a dramatic U-turn for the agency, which, only about ...
Add Yahoo as a preferred source to see more of our stories on Google. In December 2025, Moderna submitted an application to the FDA to approve the first mRNA-based flu vaccine. Catherine Falls ...
Moderna (MRNA) gained 37% YTD through February 12th, making it the 12th-best performing stock in the S&P 500. The company reduced annual operating expenses by $2B. The FDA rejected Moderna’s flu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results